No Data
No Data
Sumitomo Chemical, NEC, etc. (additional) Rating
Upgrade - bullish code | Stock name | Securities company | Previous | After the change | ------ | -------------- | ------------- | -------------- | -------------- | <4043> | Tokuyama | Mizuho | "Hold" | "Buy" | <4208> | UBE | Morgan S | "Equal weight" | "Overweight" | <7
Announcements of individual stocks for the 2024 Safety Pharmacology Society (SPS) Annual Meeting presentation (Sunday, September 22 - Wednesday, September 25, 2024)
Wacoal Holdings Corporation will present a poster presentation on our product 'CellArray-Heart' at the '2024 SPS Annual Meeting' to be held in San Diego, California, USA from September 22 (Sun) to September 25 (Wed), 2024. This conference is an important venue where an international community of experts in the field of safety pharmacology participate, including researchers, industry experts, and representatives from regulatory authorities, etc., to discuss the latest advancements.
Results of the economic value evaluation of domestic state-owned forests and the quantification project.
Prince Holdings Co., Ltd. (President: Hiroyuki Isono, Headquarters: Chuo-ku, Tokyo) has conducted an economic valuation of our domestic state-owned forests. We would like to inform you of the results and the implementation of further quantitative projects. Based on the principle that those who use wood have an obligation to plant trees, our company has been practicing sustainable forest management through reforestation for over 100 years. In addition, our forest is approximately three times the size of Tokyo, making it one of the largest privately owned forests in Japan.
Acquisition of manufacturing and sales license for first-class and second-class pharmaceuticals by Prince Pharma.
Prince Holdings Co., Ltd. (President and CEO: Hiroyuki Isono, Headquarters: Chuo-ku, Tokyo) is pleased to announce that its wholly-owned subsidiary, Oji Pharma Co., Ltd. (President and CEO: Kotaro Ishikawa, Headquarters: Chuo-ku, Tokyo), has obtained "Manufacturing and Marketing Approval" for "Class I Pharmaceutical Products" and "Class II Pharmaceutical Products" from the Tokyo Metropolitan Government. As a result, Oji Pharma is now able to manufacture and sell prescription pharmaceuticals as well as otc pharmaceuticals. Our company aims to produce wood-derived sulfate.
Three key points to focus on in the morning session ~ Shifting to australian small/mid cap amid waiting for nvidia earnings ~
In the morning session of the 28th, attention should be paid to the following three points: ■ Shifting to Australian small/mid cap amid anticipation of nvidia's earnings ■ DyDo, 25/1 financial estimates, operating profit increased by 17.9% to 4.4 billion yen ■ Morning session focus: Oji HD, increased production of film for electric vehicles, new facilities to start operating in November ■ In the midst of awaiting nvidia's earnings, the Japanese stock market on the 28th is likely to see a stalemate in market development. In the U.S. market on the 27th,
Prince HD, JTEKT, etc.
Prince HD <3861> increases production of film for electric car capacitors, new equipment to start operation in November.
No Data
No Data